ストックスクリーナーアプリを入手
9.59
0.63%
0.06
アフターアワーズ：
9.53
-0.06
-0.63%
前日終値:
$9.53
開ける：
$9.65
24時間の取引高:
1.72M
Relative Volume:
1.08
時価総額：
$3.01B
収益：
$2.68B
当期純損益:
$-184.45M
株価収益率:
-14.09
EPS:
-0.6805
ネットキャッシュフロー:
$229.23M
1週間 パフォーマンス:
+1.48%
1か月 パフォーマンス:
+20.48%
6か月 パフォーマンス:
+22.48%
1年 パフォーマンス:
+19.13%
1日の値動き範囲:
$9.565
$9.79
1週間の範囲:
$9.22
$9.79
52週間の値動き範囲:
$6.685
$9.79
Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile
名前
Amneal Pharmaceuticals Inc
セクター
電話
908-947-3120
住所
400 Crossing Boulevard, 3rd Floor, Bridgewater
AMRX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
AMRX
Amneal Pharmaceuticals Inc
|
9.59 | 2.91B | 2.68B | -184.45M | 229.23M | -0.6805 |
|
ZTS
Zoetis Inc
|
156.62 | 67.51B | 9.39B | 2.62B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.52 | 47.88B | 29.96B | 957.25M | 4.77B | 0.304 |
|
HLN
Haleon Plc Adr
|
9.82 | 43.42B | 14.26B | 1.98B | 2.47B | 0.4347 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
18.46 | 20.72B | 16.70B | -157.13M | 1.19B | -0.155 |
|
UTHR
United Therapeutics Corp
|
312.23 | 14.21B | 2.99B | 1.21B | 1.13B | 25.06 |
Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-06-06 | 開始されました | Goldman | Buy |
| 2025-02-24 | アップグレード | JP Morgan | Neutral → Overweight |
| 2024-09-06 | アップグレード | JP Morgan | Underweight → Neutral |
| 2021-04-07 | 再開されました | RBC Capital Mkts | Sector Perform |
| 2021-03-08 | アップグレード | Goldman | Sell → Buy |
| 2020-12-14 | アップグレード | Barclays | Equal Weight → Overweight |
| 2020-12-14 | アップグレード | Guggenheim | Neutral → Buy |
| 2020-07-27 | 開始されました | Goldman | Sell |
| 2020-05-12 | アップグレード | Guggenheim | Sell → Neutral |
| 2019-12-12 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2019-11-12 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2019-11-07 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2019-07-22 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2019-07-11 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-07-08 | アップグレード | Piper Jaffray | Neutral → Overweight |
| 2019-06-11 | 開始されました | Barclays | Equal Weight |
| 2019-05-21 | アップグレード | Raymond James | Mkt Perform → Strong Buy |
| 2019-03-20 | 開始されました | SunTrust | Buy |
| 2019-03-08 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2018-12-14 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2018-10-16 | ダウングレード | SunTrust | Buy → Hold |
| 2018-08-13 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-07-23 | 開始されました | Morgan Stanley | Overweight |
| 2018-06-22 | 開始されました | B. Riley FBR, Inc. | Buy |
すべてを表示
Amneal Pharmaceuticals Inc (AMRX) 最新ニュース
Amneal Pharmaceuticals Inc. Breaks Losing Streak — Is the Trend ReversingGap Up & Comprehensive Market Scan Insights - newsyoung.net
Amneal Pharmaceuticals Inc. Reversal Rally May Surprise BearsMarket Movers & Safe Capital Growth Tips - sundaytimes.kr
How Amneal Pharmaceuticals Inc. stock performs during market volatility2025 Top Gainers & Intraday High Probability Setup Alerts - thegnnews.com
Is Amneal Pharmaceuticals Inc. showing insider buyingNew Guidance & Breakout Confirmation Alerts - thegnnews.com
Major Insider Sales Shake Up Amneal Pharmaceuticals! - TipRanks
Amneal Pharma EVP Shah sells $666k in shares By Investing.com - Investing.com Canada
Quant Funds Rotate Into Amneal Pharmaceuticals Inc. StockJuly 2025 Final Week & Weekly Stock Performance Updates - sundaytimes.kr
Can Amneal Pharmaceuticals Inc. expand into new marketsWeekly Investment Report & Weekly Stock Breakout Alerts - kangso.co.kr
Amneal Pharmaceuticals stock hits 52-week high at 9.48 USD By Investing.com - Investing.com Australia
Amneal Pharmaceuticals stock hits 52-week high at 9.48 USD - Investing.com
Wall Street Analysts See a 27.66% Upside in Amneal (AMRX): Can the Stock Really Move This High? - Yahoo Finance
Avantor, Viatris, and Amneal Stocks Trade Up, What You Need To Know - Yahoo Finance
Amneal Will End Sale of Calcium-Drip Copies in Patent-Suit Pact - Bloomberg Law News
Amneal Pharmaceuticals Insider Sold Shares Worth $302,596, According to a Recent SEC Filing - MarketScreener
Here's Why Momentum in Amneal (AMRX) Should Keep going - Yahoo Finance
AMRX Q2 Deep Dive: New Product Launches and Specialty Momentum Shape Guidance - ca.finance.yahoo.com
Revvity, Avantor, Azenta, Bio-Techne, and Amneal Shares Skyrocket, What You Need To Know - TradingView
Is Amneal Pharmaceuticals Inc. forming a bullish divergenceGuaranteed Profit Setup Watchlist - newsyoung.net
Truist Financial Maintains a Buy on Amneal Pharmaceuticals (AMRX) With an $8 PT - MSN
Brown Rudnick Represents Amneal Pharmaceuticals LLC in a $2.1 Billion Term Loan Credit Facility - Brown Rudnick
‘Made-In-America’ Amneal Does Not Fear Trump’s Proposed ‘Chaotic’ Triple-Digit Tariffs On Drugs - insights.citeline.com
Amneal Pharmaceuticals Inc. Stock Poised for Technical ComebackRisk Controlled Picks With Real Returns Outlined - beatles.ru
Published on: 2025-08-11 02:04:05 - metal.it
Amneal raises 2025 guidance and targets $300M–$500M peak CREXONT sales as new launches accelerate - MSN
Published on: 2025-08-10 19:02:24 - metal.it
Earnings Beat: Amneal Pharmaceuticals, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models - ca.finance.yahoo.com
Amneal 2025 Q2 Earnings Strong Performance as Net Income Surges 112% - AInvest
Amneal (AMRX) Q2 EPS Jumps 56% - AOL.com
Results: Amneal Pharmaceuticals, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates - simplywall.st
Amneal Pharma Reports Strong Q2 2025 Results - The Globe and Mail
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Q2 2025 Earnings Call Transcript - Insider Monkey
Amneal Pharmaceuticals Reports Strong Q2 2025 Results - The Globe and Mail
Amneal Pharmaceuticals Q2 2025 Earnings: EPS Beats Estimates, Revenue Falls Short - AInvest
Amneal: Q2 Earnings Snapshot - New Haven Register
Amneal Pharmaceuticals Inc (AMRX) Q2 2025 Earnings Call Highlights: Strong Growth and Raised ... By GuruFocus - Investing.com Canada
Amneal Pharma’s Optimistic Q2 Earnings Call Highlights - TipRanks
Amneal Pharmaceuticals' 2025Q2 Earnings Call: Key Contradictions on RYTARY, CREXONT, and Margin Strategies - AInvest
AMNEAL PHARMACEUTICALS Q2 2025 Earnings Call Transcript - MarketBeat
Earnings call transcript: Amneal Pharma Q2 2025 EPS beats forecast - Investing.com
Earnings call transcript: Amneal Pharma Q2 2025 EPS beats forecast By Investing.com - Investing.com South Africa
Amneal Pharmaceuticals Stock Rises Amid Growth Signals - TipRanks
Amneal Pharmaceuticals shares rise 5.53% intraday after revising earnings guidance and raising fiscal 2025 outlook. - AInvest
Transcript : Amneal Pharmaceuticals, Inc., Q2 2025 Earnings Call, Aug 05, 2025 - MarketScreener
Amneal Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Amneal (AMRX) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
Amneal Raises Outlook Even As Revenue Falls Short - Finimize
Knight Therapeutics Submits CREXONT Marketing Authorization Application in Mexico - AInvest
Amneal Pharmaceuticals Lifts Annual Earnings Outlook As Q2 Net Income Surges; Pre-Market Stock Up - Nasdaq
Amneal Pharmaceuticals (AMRX) Q2 Earnings Top Estimates - Yahoo Finance
Amneal Pharmaceuticals Surpasses Q2 Earnings ExpectationsNews and Statistics - IndexBox
Amneal Pharmaceuticals, Inc. Revises Earnings Guidance for the Year Ending December 31, 2025 - MarketScreener
Amneal Pharmaceuticals Inc (AMRX) 財務データ
収益
当期純利益
現金流量
EPS
Amneal Pharmaceuticals Inc (AMRX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Konidaris Tasos | Executive Vice President & CFO |
Aug 15 '25 |
Sale |
9.43 |
219,159 |
2,066,669 |
122,152 |
| Konidaris Tasos | Executive Vice President & CFO |
Aug 13 '25 |
Sale |
9.22 |
161,365 |
1,487,785 |
460,517 |
| Konidaris Tasos | Executive Vice President & CFO |
Aug 14 '25 |
Sale |
9.30 |
119,206 |
1,108,616 |
341,311 |
2.37%
0.37%
大文字化:
|
ボリューム (24 時間):